caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1356369946

Mark LitwinMD

UrologyLos Angeles, CAI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
REFERRAL NETWORK

Where Mark Litwin's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 5 inbound referrers · 6 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
Jianyu Rao
Pathology · Los Angeles, CA
1763
Neda Moatamed
Pathology · Los Angeles, CA
1235
Unilab Corporation
Clinical Laboratory · West Hills, CA
1233
David Lu
Pathology · Los Angeles, CA
1128
REGENTS OF THE UNIV OF CALIFORNIA1123
Refers patients to
Outbound — where patients go next
PhysicianPatientsVisits
REGENTS UNIV OF CALIF LOS ANGELES112416
REGENTS OF THE UNIV OF CALIFORNIA1941
Unilab Corporation
Clinical Laboratory · West Hills, CA
1223
Jiaoti Huang
Pathology · Los Angeles, CA
1227
HIRSCHOWITZ, SHARON1226
CEDARS-SINAI MEDICAL CENTER1123
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
170
Unique beneficiaries
—
Total services
222
Distinct HCPCS
7
Medicare payment
$29K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 942 Urology providers in CA — below median (cohort median 1,637).
PRESCRIBING · PART D · 2024
Total Rx claims
19
Beneficiaries
—
Total drug cost
$356
Distinct drugs
1
Brand share
0.0%
Top prescribed drugs
Tamsulosin Hcl19 claims
QUALITY · MIPS · 2024
Final MIPS score
89.3
Quality
80.6
Cost
73.8
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.60%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
No data available for this provider in 2024.